CA2508022C - Mastitis treatment - Google Patents

Mastitis treatment Download PDF

Info

Publication number
CA2508022C
CA2508022C CA2508022A CA2508022A CA2508022C CA 2508022 C CA2508022 C CA 2508022C CA 2508022 A CA2508022 A CA 2508022A CA 2508022 A CA2508022 A CA 2508022A CA 2508022 C CA2508022 C CA 2508022C
Authority
CA
Canada
Prior art keywords
prednisolone
treatment
composition according
cephapirin
cephalosporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2508022A
Other languages
English (en)
French (fr)
Other versions
CA2508022A1 (en
Inventor
Peter Gerardus Franciscus Cox.
Joseph Antonius Clemens Maria Lohuis
Selma Marianne Hensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32524018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2508022(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CA2508022A1 publication Critical patent/CA2508022A1/en
Application granted granted Critical
Publication of CA2508022C publication Critical patent/CA2508022C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2508022A 2002-12-16 2003-12-10 Mastitis treatment Expired - Lifetime CA2508022C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02080265.8 2002-12-16
EP02080265 2002-12-16
PCT/EP2003/014051 WO2004054538A1 (en) 2002-12-16 2003-12-10 Mastitis treatment

Publications (2)

Publication Number Publication Date
CA2508022A1 CA2508022A1 (en) 2004-07-01
CA2508022C true CA2508022C (en) 2012-01-31

Family

ID=32524018

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2508022A Expired - Lifetime CA2508022C (en) 2002-12-16 2003-12-10 Mastitis treatment

Country Status (9)

Country Link
US (1) US7812009B2 (en:Method)
EP (1) EP1585497B1 (en:Method)
JP (2) JP5162080B2 (en:Method)
AT (1) ATE390124T1 (en:Method)
AU (1) AU2003290015A1 (en:Method)
CA (1) CA2508022C (en:Method)
DE (1) DE60320034T2 (en:Method)
ES (1) ES2300634T3 (en:Method)
WO (1) WO2004054538A1 (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300634T3 (es) 2002-12-16 2008-06-16 Intervet International Bv Tratamiento de mastitis con una combinacion de prednisolona con cefalosporina.
CN100368016C (zh) * 2005-04-01 2008-02-13 北京大北农农业科技研究院 治疗奶牛乳房炎的乳房灌注液及其制备方法
ES2346573T3 (es) * 2005-10-29 2010-10-18 Intervet International Bv Composiciones de cefquinoma y metodos para su uso.
WO2008025773A1 (en) * 2006-08-30 2008-03-06 Intervet International B.V. Pharmaceutical compositions comprising cefquinome
CN101148451A (zh) * 2007-05-16 2008-03-26 好维股份有限公司 一种口腔药物及口腔护理用品
WO2011074992A1 (en) * 2009-12-15 2011-06-23 Dec International Nz Limited Treatment composition and method
EP2510944A1 (en) * 2011-04-15 2012-10-17 National University of Ireland, Galway Treatment of bacterial infections
JP2014516950A (ja) * 2011-05-12 2014-07-17 インターベット インターナショナル ベー． フェー． 乳腺炎の治療
JP6271443B2 (ja) 2012-02-27 2018-01-31 バイエル・ニュージーランド・リミテッド 制御放出組成物およびその使用方法
EP3031464B1 (en) 2013-05-17 2020-04-01 Asahi Calpis Wellness Co., Ltd. Preventive or therapeutic agent for ruminant animal mastitis
JP2018525985A (ja) * 2015-07-29 2018-09-13 ジーナス ピーエルシー 乳生産量を改善するための雌牛の育種方法
ES2985441T3 (es) 2018-07-30 2024-11-05 Virbac Utilización novedosa de glucocorticoides para el tratamiento de infecciones microbianas epiteliales de un órgano que contiene fluidos con un orificio exterior natural en mamíferos
CN113209014A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效硫酸头孢喹肟混悬注射液及其制备工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU504840B2 (en) 1975-09-09 1979-11-01 Takeda Chemical Industries Ltd Medicinal compositions
JPS5234914A (en) * 1975-09-09 1977-03-17 Takeda Chem Ind Ltd Method and composition for preventing failing of milk secretion of live stocks
JPS52110816A (en) * 1976-03-15 1977-09-17 Takeda Chem Ind Ltd Medicines
ES2300634T3 (es) 2002-12-16 2008-06-16 Intervet International Bv Tratamiento de mastitis con una combinacion de prednisolona con cefalosporina.

Also Published As

Publication number Publication date
US7812009B2 (en) 2010-10-12
WO2004054538A1 (en) 2004-07-01
AU2003290015A1 (en) 2004-07-09
JP2006514642A (ja) 2006-05-11
DE60320034T2 (de) 2009-05-14
JP5162080B2 (ja) 2013-03-13
ATE390124T1 (de) 2008-04-15
JP2013035845A (ja) 2013-02-21
DE60320034D1 (de) 2008-05-08
EP1585497A1 (en) 2005-10-19
US20060058273A1 (en) 2006-03-16
EP1585497B1 (en) 2008-03-26
CA2508022A1 (en) 2004-07-01
ES2300634T3 (es) 2008-06-16

Similar Documents

Publication Publication Date Title
JP2013035845A (ja) 乳腺炎治療
RU96108290A (ru) Лекарственный препарат и способ профилактики и лечения урогенитальных инфекций
AU2004247053A1 (en) Compositions for treating infection in cattle and swine
PL209943B1 (pl) Zastosowanie moksifloksacyny stanowiącej kwas 1-cyklopropylo-6-fluoro-1,4-dihydro-8-metoksy-7-[(4aS,7aS)-oktahydro-6H-pirolo [3,4-b]pirydyn-6-ylo]-4-okso-3-chinolino-karboksylowy
Nickerson Resistance mechanisms of the bovine udder: new implications for mastitis control at the teat end
AU641698B2 (en) Method for the prevention and treatment of bovine mastitis
US5234684A (en) Method for the prevention and treatment of bovine mastitis
JP2000510842A (ja) 全身性細菌疾患の治療のための抗菌剤の局所投与
IE51846B1 (en) Pharmaceutical preparation for veterinary use and an appliance containing it
US5120711A (en) Synergistically active veterinary compositions and process for preparing same
US5342612A (en) Compositions for the treatment of mammalian diseases
Janosi et al. The use of the dry cow therapy in the control of bovine mastitis
EP1001778B1 (en) Use of a rifamycin derivative for treating mastitis in a domestic animal
KR102203849B1 (ko) 동물용 복합 항생제 조성물
EP0238207B1 (en) Bactericidal mixtures
Mengelers et al. Prevention of pleuropneumonia in pigs by in‐feed medication with sulphadimethoxine and sulphamethoxazole in combination with trimethoprim
WO2004032899A1 (en) Antibiotic formulation for intramammary administration in milking animals
EP4267146B1 (en) An orthosomycin antimicrobial compound for use in methods of treating mastitis
CA2079328C (en) Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof
IE921419A1 (en) Treatment of mastitis
CN1176661C (zh) 用于防治奶牛乳房炎的基因药物
FR2563433A1 (fr) Nouvelles compositions pharmaceutiques comprenant de l'oxytetracycline et un acide organique ayant une activite antimicrobienne et procede pour leur preparation
Lescene et al. Experimental Arguments For Rational Use of Spiramycin (Embonate) Against Respiratory Infections in Calves

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20231211